CATX Stock Overview
Perspective Therapeutics, Inc., together with its subsidiaries, develops, manufactures, and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States and internationally.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 2/6 |
Past Performance | 0/6 |
Financial Health | 5/6 |
Dividends | 0/6 |
Perspective Therapeutics, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$1.20 |
52 Week High | US$1.36 |
52 Week Low | US$0.20 |
Beta | 1.53 |
1 Month Change | 33.33% |
3 Month Change | 163.74% |
1 Year Change | 110.53% |
3 Year Change | 10.09% |
5 Year Change | 223.28% |
Change since IPO | 20.00% |
Recent News & Updates
Shareholder Returns
CATX | US Biotechs | US Market | |
---|---|---|---|
7D | 0% | 0.9% | 0.4% |
1Y | 110.5% | 10.3% | 28.8% |
Return vs Industry: CATX exceeded the US Biotechs industry which returned 9.6% over the past year.
Return vs Market: CATX exceeded the US Market which returned 29.5% over the past year.
Price Volatility
CATX volatility | |
---|---|
CATX Average Weekly Movement | 20.0% |
Biotechs Industry Average Movement | 11.6% |
Market Average Movement | 6.0% |
10% most volatile stocks in US Market | 16.9% |
10% least volatile stocks in US Market | 3.0% |
Stable Share Price: CATX's share price has been volatile over the past 3 months.
Volatility Over Time: CATX's weekly volatility (20%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1998 | 91 | Thijs Spoor | https://www.perspectivetherapeutics.com |
Perspective Therapeutics, Inc., together with its subsidiaries, develops, manufactures, and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States and internationally. The company offers CS-1 Cesium-131 brachytherapy seeds for the treatment of prostate, brain, lung, head and neck, gynecological, pelvic/abdominal, and colorectal cancers. It sells its products to facilities or physician practices that utilize various surgical facilities.
Perspective Therapeutics, Inc. Fundamentals Summary
CATX fundamental statistics | |
---|---|
Market cap | US$704.16m |
Earnings (TTM) | -US$29.01m |
Revenue (TTM) | US$6.31m |
111.6x
P/S Ratio-24.3x
P/E RatioIs CATX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
CATX income statement (TTM) | |
---|---|
Revenue | US$6.31m |
Cost of Revenue | US$5.98m |
Gross Profit | US$326.00k |
Other Expenses | US$29.34m |
Earnings | -US$29.01m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -0.049 |
Gross Margin | 5.17% |
Net Profit Margin | -459.89% |
Debt/Equity Ratio | 1.8% |
How did CATX perform over the long term?
See historical performance and comparison